Zaynich Approval: How Big Is It For Wockhardt?

What Drove This Radical Antibiotic Research?

Scientific Bet, Business Bet, Or Innovation?

How Did You Stay The Course Through Crisis

Can This Innovation Stay Ahead Of Rivals?

Will Zaynich Lead To Higher R&D Investments?

Is Wockhardt Entering Its Biggest Growth Phase

Can Zaynich Thrive Despite A Smaller Market?

Message To India's Pharma Innovators?

What Can Entrepreneurs Learn From Persistence?

Wockhardt's FDA approval of Zaynich marks a historic first, the only drug entirely discovered and developed by an Indian company to clear US-FDA scrutiny. ET’s pharma editor Vikas Dandekar and Rica Bhattacharyya talk to Habil Khorakiwala, Chairperson of Wockhardt who unpacks the 25-year innovation journey behind this milestone. From a deliberate pivot to antibiotics when big pharma was exiting the space, to navigating financial turbulence, asset sales, and regulatory hurdles, Khorakiwala reflects on strategic patience and scientific conviction. He also outlines peak sales projections of $1.5–2 billion, the US commercial roadmap led by daughter Zahabiya, and a robust pipeline of blockbusters ahead.

You can follow Vikas Dandekar on his social media: X or Linkedin and Rica Bhattacharyya on her X and Linkedin



Check out other interesting episodes like:ET Deep Dive: Swipe Left on Reality,India wants manufacturing at 25% of GDP — will AI in factories help?, Tanay Kothari Wants To Kill The Keyboard,From Doer to Director: The LinkedIn Playbook for the AI Agea, Semaglutide Goes Generic: Big Pharma’s Moat Breaks  and much more.


Catch the latest episode of ‘The Morning Brief’ on The Economic Times Online, Spotify, Apple Podcasts, JioSaavn, Amazon Music and Youtube.

Wockhardt's FDA approval of Zaynich marks a historic first, the only drug entirely discovered and developed by an Indian company to clear US-FDA scrutiny. ET&rsquo;s pharma editor Vikas Dandekar and Rica Bhattacharyya talk to Habil Khorakiwala, Chairperson of Wockhardt who unpacks the 25-year innovation journey behind this milestone. From a deliberate pivot to antibiotics when big pharma was exiting the space, to navigating financial turbulence, asset sales, and regulatory hurdles, Khorakiwala reflects on strategic patience and scientific conviction. He also outlines peak sales projections of $1.5&ndash;2 billion, the US commercial roadmap led by daughter Zahabiya, and a robust pipeline of blockbusters ahead. You can follow Vikas Dandekar on his social media: <a href="https://twitter.com/VikasReports">X</a> or <a href="https://www.linkedin.com/in/vikas-dandekar-2a0a619">Linkedin</a> and Rica Bhattacharyya on her <a href="https://x.com/RicaB_ET">X</a> and <a href="https://www.linkedin.com/in/rica-bhattacharyya-72b24a11/">Linkedin</a> 
Check out other interesting episodes like:<a href="https://podcasts.apple.com/in/podcast/et-deep-dive-swipe-left-on-reality/id1568661777?i=1000763614435&amp;l=te">ET Deep Dive: Swipe Left on Reality</a>,<a href="https://podcasts.apple.com/in/podcast/india-wants-manufacturing-at-25-of-gdp-will-ai-in/id1568661777?i=1000760758322">India wants manufacturing at 25% of GDP &mdash; will AI in factories help?</a>, <a href="https://podcasts.apple.com/us/podcast/tanay-kothari-wants-to-kill-the-keyboard/id1568661777?i=1000758892178">Tanay Kothari Wants To Kill The Keyboard</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000738205536"> </a><a href="https://podcasts.apple.com/in/podcast/from-doer-to-director-the-linkedin-playbook-for-the-ai-age/id1568661777?i=1000756242616">From Doer to Director: The LinkedIn Playbook for the AI Agea</a>, <a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777?i=1000756051799">Semaglutide Goes Generic: Big Pharma&rsquo;s Moat Breaks</a>&nbsp; and<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> much more</a>.
 Catch the latest episode of &lsquo;The Morning Brief&rsquo; on<a href="https://economictimes.indiatimes.com/podcast?from=mdr"> The Economic Times Online</a>,<a href="https://open.spotify.com/show/6PL5kfPbwURBEu6fHCVTOL?si=26ec0fbfa7134fea"> Spotify</a>,<a href="https://podcasts.apple.com/in/podcast/the-morning-brief/id1568661777"> Apple Podcasts</a>,<a href="https://www.jiosaavn.com/shows/the-morning-brief/1/GNPiFQD2xpY_"> JioSaavn</a>,<a href="https://music.amazon.in/podcasts/f378141f-9afb-495d-83da-9b08ec5047ac/the-morning-brief"> Amazon Music</a> and<a href="https://www.youtube.com/@theetpodcasts"> Youtube</a>.

To make sense of the week’s hottest stories in business, economy, politics and markets, journalists from the Economic Times chat with reporters and industry leaders in this thrice-weekly (Tuesday, Thursday, Friday) podcast.

The Morning Brief

 Habil Khorakiwala on India's First FDA-Approved Antibiotic.